Concepedia

Publication | Open Access

Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial

DOIFull Paper Access

29

Citations

24

References

2016

Year

Joleen T. White, Scott D. Newsome, Bernd C. Kieseier, Robert Bermel, Yue Cui, Ali Seddighzadeh, Serena Hung, Mary Crossman, Meena Subramanyam
Therapeutic Advances in Neurological Disorders

Abstract

The treatment effect of peginterferon beta1a in patients with relapsing-remitting MS is not expected to be attenuated by immunogenicity.

References

YearCitations

Page 1